Search Clinical Trials
Sponsor Condition of Interest |
---|
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib...
Celgene
Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy and safety of mezigdomide
(CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and
dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM)
who received between 1 to 3 prior lines of therapy... expand
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure. Type: Interventional Start Date: Sep 2022 |
Randomized Study of the pdSTIMâ„¢ System (Phrenic Nerve to Diaphragm STIMulation) in Failure to Wean Mechanically...
Stimdia Medical Inc.
Ventilator Induced Diaphragm Dysfunction
This prospective, multi-center, randomized, controlled clinical trial is being conducted
to evaluate the safety and efficacy of the pdSTIM System to facilitate weaning from
mechanical ventilation through phrenic nerve stimulation. Potential subjects who are on
mechanical ventilation for at least four... expand
This prospective, multi-center, randomized, controlled clinical trial is being conducted to evaluate the safety and efficacy of the pdSTIM System to facilitate weaning from mechanical ventilation through phrenic nerve stimulation. Potential subjects who are on mechanical ventilation for at least four days and have failed at least one weaning attempt will be considered for the study. Those enrolled will be randomized in a 1:1 manner between the treatment group that is standard of care with the pdSTIM System and a Control group, which is standard of care alone. The primary endpoints focus on time to weaning and serious adverse event rates between the Treatment and Control groups. Type: Interventional Start Date: Sep 2023 |
Efficacy and Safety of Lorundrostat in Subjects with Uncontrolled and Resistant Hypertension
Mineralys Therapeutics Inc.
Hypertension
This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an
aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension
taking between 2 and 5 anti-hypertensive (AHT) medications. expand
This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications. Type: Interventional Start Date: Nov 2023 |
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
Incyte Corporation
cGVHD
The purpose of this prospective observational study is to collect data from participants
who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of
Chronic Graft Versus Host Disease(cGVHD) expand
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD) Type: Observational Start Date: Aug 2023 |
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous...
AiCuris Anti-infective Cures AG
HSV Infection
Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety
in immunocompromised subjects with acyclovir resistant or acyclovir susceptible
mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a
loading dose of 400 mg as first dose to rapidly... expand
Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or investigators choice, which can be either foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours, or Cidofovir iv 5 mg/kg body weight given once weekly, or Cidofovir 1% or 3% topical applied 2 to 4 times daily, or Imiquimod 5% topical 3 times per week) (provided the drug is nationally approved). Type: Interventional Start Date: May 2017 |
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Duke University
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started
recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018,
the registry expanded to include recruitment of participants with other chronic fibrosing
interstitial lung diseases (ILDs) with... expand
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects. Type: Observational [Patient Registry] Start Date: Jun 2014 |
Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control...
Tulane University
Hypertension
Cognitive Decline
The study will test a multifaceted strategy for implementing an intensive blood pressure
intervention protocol targeting systolic BP <120 mmHg on cognitive decline in racial
minority and low-income hypertensive patients in primary care. The proposed study will
generate urgently needed data on effective,... expand
The study will test a multifaceted strategy for implementing an intensive blood pressure intervention protocol targeting systolic BP <120 mmHg on cognitive decline in racial minority and low-income hypertensive patients in primary care. The proposed study will generate urgently needed data on effective, adoptable, and equitable intervention strategies to reduce blood pressure-related cognitive decline in low- income and minority populations. If proven effective, the implementation strategy for intensive blood pressure reduction could be adapted and scaled up in diverse primary care settings to prevent cognitive decline and clinical dementia. Type: Interventional Start Date: Oct 2019 |
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib)...
National Cancer Institute (NCI)
Advanced Renal Cell Carcinoma
Chromophobe Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Collecting Duct Carcinoma
Kidney Medullary Carcinoma
This phase II trial studies whether adding radium-223 dichloride to the usual treatment,
cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the
bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to
cancer cells and minimize harm to... expand
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone. Type: Interventional Start Date: Jul 2020 |
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering...
ECOG-ACRIN Cancer Research Group
Smoldering Plasma Cell Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or
without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in
chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the
growth of tumor cells, either by killing... expand
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma. Type: Interventional Start Date: Sep 2019 |
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
University of Alabama at Birmingham
Idiopathic Pulmonary Fibrosis
A placebo-controlled, multicenter, randomized trial to test GKT137831 in ambulatory
patients with idiopathic pulmonary fibrosis. This drug is an inhibitor of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase (NOX) isoforms. The investigators
hypothesize the drug will decrease pulmonary injury... expand
A placebo-controlled, multicenter, randomized trial to test GKT137831 in ambulatory patients with idiopathic pulmonary fibrosis. This drug is an inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) isoforms. The investigators hypothesize the drug will decrease pulmonary injury due to reactive oxygen species (ROS) generated by NOX enzymes, which are believed to play an important role in the development of IPF. Treatment with GKT137831 could result in significant benefit for a lung disease that has, until now, been almost invariably inexorable. This clinical trial represents the bedside application of a series of NOX translational and basic studies and discoveries, over several years, from the laboratory of Dr. Victor Thannickal. Type: Interventional Start Date: Sep 2020 |
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic...
Syros Pharmaceuticals
Myelodysplastic Syndromes
This study compares the efficacy of Tamibarotene in combination with azacitidine to
azacitidine in combination with placebo in participants who are Retinoic Acid Receptor
Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome
(HR-MDS), and who have not received treatment... expand
This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms. Type: Interventional Start Date: Feb 2021 |
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed...
AbbVie
Relapsed/Refractory Multiple Myeloma
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal
plasma cells in the bone marrow. The purpose of this study is to assess the safety and
toxicity of ABBV-453 in adult participants with relapsed/refractory (R/R) MM. Adverse
events and change in disease activity will... expand
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-453 in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in disease activity will be assessed. ABBV-453 is an investigational drug being developed for the treatment of R/R MM. Part 1 will be a monotherapy dose escalation phase to determine the best dose of ABBV-453. In Part 2, participants are placed in 1 of 3 groups called treatment arms. Each group receives a different treatment. Approximately 28 to 48 adult participants in Part 1 and 150 to 312 adult participants in Part 2 with R/R MM will be enrolled in the study in approximately 70 sites worldwide. In Part 1 and the Japan Cohort, Participants will receive oral ABBV-453 tablets once daily (QD) in 28-day cycles. In Part 2, Arm 1, participants will receive continuous doses of oral ABBV-453 tablets QD in combination with oral dexamethasone tablets once weekly in 28-day cycles. In Part 2, Arm 2, participants will receive continuous doses of oral ABBV-453 tablets QD in combination with subcutaneous injections of daratumumab every 1 to 4 weeks and oral dexamethasone tablets once weekly in, 28-day cycles. In Part 2, Arm 3, participants will receive continuous doses of oral ABBV-453 tablets QD in combination with subcutaneous injections of daratumumab every 1 to 4 weeks, oral lenalidomide capsules QD on Days 1-21, and oral dexamethasone tablets once weekly, in 28-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects. Type: Interventional Start Date: May 2022 |
The Allergen Reduction and Child Health Study (ARCHS)
Tulane University
Asthma in Children
The Allergen Reduction and Child Health Study (ARCHS) is a 12-month, two group randomized
control trial of children with asthma and who are exposed to cockroaches. Children ages 5
- 17 living in the Greater New Orleans area will be recruited from a variety of clinic
and community settings. The overall... expand
The Allergen Reduction and Child Health Study (ARCHS) is a 12-month, two group randomized control trial of children with asthma and who are exposed to cockroaches. Children ages 5 - 17 living in the Greater New Orleans area will be recruited from a variety of clinic and community settings. The overall goal of the study is to improve patient-centered asthma outcomes (asthma symptom days, health care utilization, asthma control and quality of life) by targeting one key allergen - cockroach exposure in the child's home. The investigators propose a simple intervention of insecticidal bait that is low cost, simple to implement, and which is lower toxicity than other forms of pest control. The reduction in the number of cockroaches in the home is an environmental outcome that is patient-centered and is likely to add to its acceptance by families of children with asthma. Type: Interventional Start Date: Nov 2020 |
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With...
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Relapsed Diffuse Large B-cell Lymphoma
Refractory Diffuse Large B-cell Lymphoma
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of
DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in
subjects with relapsed or refractory DLBCL. expand
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL. Type: Interventional Start Date: Jun 2021 |
- Previous
- Next